GLP1R and deep vein thrombosis: Patients were divided into two cohorts (GLP-1 vs. DPP4i), and the primary outcome was all thromboembolic events (cerebral infarction, myocardial infarction [MI], deep vein thrombosis [DVT], pulmonary embolism [PE]) within 5 years after GLP-1 analog or DPP4i start.